Imiquad Cream: Targeted Topical Immunotherapy for Skin Conditions
| Product dosage: 12.5mg | |||
|---|---|---|---|
| Package (num) | Per sachet | Price | Buy |
| 12 | $4.30 | $51.60 (0%) | 🛒 Add to cart |
| 24 | $2.87 | $103.20 $68.80 (33%) | 🛒 Add to cart |
| 36 | $2.63 | $154.80 $94.60 (39%) | 🛒 Add to cart |
| 60 | $2.44 | $258.00 $146.20 (43%) | 🛒 Add to cart |
| 96 | $2.24
Best per sachet | $412.80 $215.00 (48%) | 🛒 Add to cart |
Similar products
Imiquad Cream is a prescription topical immunomodulator indicated for the treatment of external genital and perianal warts/condylomata acuminata in adults, superficial basal cell carcinoma, and actinic keratosis. It contains the active ingredient imiquimod, which works by stimulating the local immune response to help the body fight abnormal cells. This cream represents a non-invasive therapeutic option that can be self-administered, offering convenience alongside clinical efficacy. Proper diagnosis and medical supervision are essential to determine appropriate use and monitor treatment response.
Features
- Contains 5% imiquimod as the active pharmaceutical ingredient
- Available in single-use packets or multi-use tubes (e.g., 12 or 24 packets per box)
- White-to-light-yellow oil-in-water emulsion cream formulation
- Typically supplied in 250 mg single-use sachets or 5 g/12.5 g tubes
- Requires refrigeration storage (2°C–8°C) before opening; may be stored at room temperature after opening for a limited period
- Applied topically; not for oral, ophthalmic, or intravaginal use
Benefits
- Stimulates local immune response to target and eliminate abnormal skin cells and lesions
- Provides a non-invasive alternative to surgical procedures such as excision or cryotherapy
- Allows convenient at-home application under medical guidance, reducing clinic visits
- Demonstrates high clearance rates for approved indications when used as directed
- May reduce recurrence rates of certain conditions compared to destructive therapies
- Minimizes scarring risk compared to surgical interventions
Common use
Imiquad Cream is primarily prescribed for three dermatological conditions. For external genital and perianal warts, it is used in immunocompetent adults to eliminate visible warts. In superficial basal cell carcinoma (sBCC), it is indicated for immunocompetent adults with histologically confirmed primary sBCC on the trunk, neck, or extremities (excluding hands and feet), with a maximum tumor diameter of 2.0 cm, when surgical methods are less appropriate. For actinic keratosis, it is used on the face or scalp in immunocompetent adults. Treatment duration and frequency vary by indication, typically ranging from several weeks to a full 16-week course.
Dosage and direction
Apply a thin layer of Imiquad Cream to cover the treatment area, including approximately 1 cm of surrounding skin. Gently rub in the cream until it vanishes. Wash hands before and after application. For genital/perianal warts: Apply three times per week (e.g., Monday, Wednesday, Friday) prior to normal sleeping hours, leaving on for 6-10 hours before washing with mild soap and water. Treatment continues for up to 16 weeks or until clearance. For sBCC: Apply five times per week for 6 weeks, with the cream left on for approximately 8 hours. For actinic keratosis: Apply twice per week for 16 weeks, leaving on for 8 hours before washing. Do not occlude the treatment area unless directed by a physician.
Precautions
Use only as prescribed and for the condition diagnosed. Avoid contact with eyes, lips, and nostrils. Sexual contact should be avoided while the cream is on the skin. The medication may weaken condoms and diaphragms. Application may cause local skin reactions including redness, swelling, itching, burning, and erosion; these typically resolve after treatment cessation. Sun exposure should be minimized during treatment. Not recommended for immunocompromised patients unless specifically indicated. Use during pregnancy only if clearly needed and potential benefits justify potential risks. Nursing mothers should consult their physician before use.
Contraindications
Hypersensitivity to imiquimod or any component of the formulation. Should not be used until a complete diagnosis has been established. Not for use on open wounds or broken skin. Contraindicated in patients with autoimmune disorders or those undergoing immunosuppressive therapy unless specifically advised by a healthcare provider. Not recommended for treatment of internal (mucosal) warts. Should not be used in children under 18 years of age.
Possible side effects
Very common (≥1/10): application site reactions (erythema, edema, itching, burning, pain, tenderness, erosion, ulceration, flaking, scabbing, crusting), headache, fatigue. Common (≥1/100 to <1/10): fever, nausea, diarrhea, myalgia, influenza-like symptoms, fungal infections. Uncommon (≥1/1,000 to <1/100): lymph node enlargement, dizziness. Rare (≥1/10,000 to <1/1,000): hypopigmentation or hyperpigmentation at application site. Very rare (<1/10,000): severe skin reactions, autoimmune disorders. Most local reactions are mild to moderate and typically resolve within several weeks after treatment completion.
Drug interaction
Formal drug interaction studies have not been conducted with topical imiquimod. Concomitant use with other topical medications on the same area is not recommended. May potentially interact with other immunomodulators or immunosuppressive drugs. Caution is advised when using concurrently with corticosteroids on treated areas. Inform your physician about all medications, including prescription, over-the-counter, and herbal products.
Missed dose
If a dose is missed, apply it as soon as remembered, unless it is nearly time for the next application. Do not double the dose to make up for a missed application. Resume the regular dosing schedule. If uncertain, contact your healthcare provider for guidance. Consistent application according to the prescribed schedule is important for optimal efficacy.
Overdose
Topical overdose may result in severe local skin reactions. Systemic overdose is unlikely due to minimal absorption, but if the cream is ingested orally, seek immediate medical attention. Symptoms of oral ingestion may include nausea, vomiting, and fatigue. Treatment is symptomatic and supportive. In case of topical overdose, wash the area thoroughly with soap and water and monitor for severe skin reactions.
Storage
Store unopened packets or tubes refrigerated at 2°C–8°C (36°F–46°F). Do not freeze. Once opened, the cream may be stored at room temperature up to 25°C (77°F) for a limited period (consult package insert for specific duration, typically several weeks). Keep in the original container, tightly closed. Protect from light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment recommendations. Do not initiate, modify, or discontinue treatment without medical supervision. The manufacturer and distributor are not liable for any incorrect use or self-diagnosis. Full prescribing information should be reviewed before use.
Reviews
Clinical studies demonstrate Imiquad Cream achieves complete clearance in approximately 50-60% of genital wart patients after 16 weeks, with 70-80% achieving ≥75% clearance. For superficial basal cell carcinoma, histologic clearance rates of 80-90% have been reported at 12 weeks post-treatment. In actinic keratosis, complete clearance rates of 45-55% have been observed. Most patients experience local skin reactions indicating immune activation, with these reactions generally resolving after treatment completion. Patient satisfaction surveys indicate preference for topical treatment over surgical options when appropriate, though compliance with the full treatment regimen is important for optimal outcomes.